Health Trials

About this trial

The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to docetaxel.

Eligibility criteria

Qualifiers

At least 18 years old and has provided informed consent.

Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

Pathologically confirmed NSCLC, either locally advanced or metastatic, not amenable to curative surgery or radiotherapy.

Measurable disease per RECIST v1.1.

Disqualifiers

Prior therapy with direct RAS-targeted therapy or docetaxel.

Untreated central nervous system (CNS) metastases.

Medically significant comorbidities (significant cardiovascular disease, lung disease, or impaired GI function).

Ongoing anticancer therapy.

Trial design

Treatments tested in this trial

  • daraxonrasib
  • docetaxel

Treatment groups

590 Participants
are divided into 2 treatment groups

Locations

151
Australia
Blacktown Medical Oncology Research2148, BlacktownNew South Wales, Australia
Blacktown Medical Oncology Research, Blacktown Hospital2148, BlacktownNew South Wales, Australia
Chris O'Brien Lifehouse2050, CamperdownNew South Wales, Australia
St. George Private Hospital Clinical Trials Unit2217, KogarahNew South Wales, Australia

Sponsors and collaborators

Revolution Medicines, Inc.

Lead sponsor

Source ClinicalTrials.gov